{"product_id":"memorial-sloan-kettering-cancer-center-10th-annual-msk-symposium-on-lymphoma-2026","title":"Memorial Sloan Kettering Cancer Center 10th Annual MSK Symposium on Lymphoma 2026","description":"\u003cdiv class=\"tab-panels\"\u003e\r\n\u003cdiv id=\"tab-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content active\" role=\"tabpanel\" aria-labelledby=\"tab-title-description\"\u003e\r\n\u003ch1 data-section-id=\"1wnn5ts\" data-start=\"0\" data-end=\"83\"\u003eMemorial Sloan Kettering Cancer Center 10th Annual MSK Symposium on Lymphoma 2026\u003c\/h1\u003e\r\n\u003ch2 data-section-id=\"1di1av8\" data-start=\"85\" data-end=\"163\"\u003eAdvanced Updates in Lymphoma Diagnosis, Classification \u0026amp; Precision Oncology\u003c\/h2\u003e\r\n\u003cp data-start=\"165\" data-end=\"630\"\u003eThe \u003cstrong data-start=\"169\" data-end=\"215\"\u003e10th Annual MSK Symposium on Lymphoma 2026\u003c\/strong\u003e marks a decade of excellence in lymphoma education, bringing together internationally recognized experts in hematology, oncology, pathology, and translational research. Hosted by \u003cstrong data-start=\"395\" data-end=\"445\"\u003eMemorial Sloan Kettering Cancer Center (MSKCC)\u003c\/strong\u003e, this one-and-a-half-day symposium provides a comprehensive review of the rapidly evolving landscape of lymphoma diagnosis, classification, disease biology, and therapeutic innovation.\u003c\/p\u003e\r\n\u003cp data-start=\"632\" data-end=\"971\"\u003eDesigned for clinicians involved in the care of patients with lymphoma, the program explores recent advances in the \u003cstrong data-start=\"748\" data-end=\"812\"\u003eWHO and International Consensus Classification (ICC) systems\u003c\/strong\u003e, emerging biomarkers, novel targeted therapies, cellular immunotherapies, and management strategies for both newly diagnosed and relapsed\/refractory lymphoma.\u003c\/p\u003e\r\n\u003cp data-start=\"973\" data-end=\"1180\"\u003eThrough keynote presentations, case-based panel discussions, and expert clinical guidance, participants gain practical insights into applying the latest scientific discoveries to individualized patient care.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"1182\" data-end=\"1185\"\u003e\r\n\r\n\u003ch2 data-section-id=\"189qedo\" data-start=\"1187\" data-end=\"1205\"\u003eProduct Details\u003c\/h2\u003e\r\n\u003cul data-start=\"1207\" data-end=\"1473\"\u003e\r\n \t\u003cli data-section-id=\"1vtdiqu\" data-start=\"1207\" data-end=\"1258\"\u003e\n\u003cstrong data-start=\"1209\" data-end=\"1220\"\u003eCourse:\u003c\/strong\u003e 10th Annual MSK Symposium on Lymphoma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"5hgpta\" data-start=\"1259\" data-end=\"1321\"\u003e\n\u003cstrong data-start=\"1261\" data-end=\"1274\"\u003eProvider:\u003c\/strong\u003e Memorial Sloan Kettering Cancer Center (MSKCC)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1mtv5va\" data-start=\"1322\" data-end=\"1359\"\u003e\n\u003cstrong data-start=\"1324\" data-end=\"1341\"\u003eCourse Dates:\u003c\/strong\u003e April 10–11, 2026\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"tqtxaj\" data-start=\"1360\" data-end=\"1415\"\u003e\n\u003cstrong data-start=\"1362\" data-end=\"1375\"\u003eLocation:\u003c\/strong\u003e Zuckerman Research Center, New York, NY\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"bqqejt\" data-start=\"1416\" data-end=\"1449\"\u003e\n\u003cstrong data-start=\"1418\" data-end=\"1429\"\u003eFormat:\u003c\/strong\u003e In-Person \u0026amp; Virtual\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1yzdop2\" data-start=\"1450\" data-end=\"1473\"\u003e\n\u003cstrong data-start=\"1452\" data-end=\"1468\"\u003eCourse Year:\u003c\/strong\u003e 2026\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"1475\" data-end=\"1478\"\u003e\r\n\r\n\u003ch2 data-section-id=\"a88ac2\" data-start=\"1480\" data-end=\"1499\"\u003eProgram Overview\u003c\/h2\u003e\r\n\u003cp data-start=\"1501\" data-end=\"1605\"\u003eThis advanced lymphoma symposium provides state-of-the-art updates across the spectrum of lymphoma care.\u003c\/p\u003e\r\n\u003cp data-start=\"1607\" data-end=\"1634\"\u003eKey areas of focus include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1636\" data-end=\"1967\"\u003e\r\n \t\u003cli data-section-id=\"ab7ur6\" data-start=\"1636\" data-end=\"1654\"\u003eLymphoma Biology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"172r8qo\" data-start=\"1655\" data-end=\"1698\"\u003eWHO \u0026amp; ICC Lymphoma Classification Updates\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1rl7dka\" data-start=\"1699\" data-end=\"1727\"\u003eDiagnostic Hematopathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ktscb5\" data-start=\"1728\" data-end=\"1746\"\u003eB-Cell Lymphomas\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1wwnhqf\" data-start=\"1747\" data-end=\"1765\"\u003eT-Cell Lymphomas\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1a5d2v7\" data-start=\"1766\" data-end=\"1784\"\u003eHodgkin Lymphoma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"f8agoy\" data-start=\"1785\" data-end=\"1814\"\u003eRelapsed\/Refractory Disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"6tnfa5\" data-start=\"1815\" data-end=\"1835\"\u003eTargeted Therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"y0me1i\" data-start=\"1836\" data-end=\"1851\"\u003eImmunotherapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1jwpj1j\" data-start=\"1852\" data-end=\"1875\"\u003eBispecific Antibodies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"7dupes\" data-start=\"1876\" data-end=\"1896\"\u003eCAR T-Cell Therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1yfjtm\" data-start=\"1897\" data-end=\"1917\"\u003ePrecision Medicine\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"7pf4uz\" data-start=\"1918\" data-end=\"1942\"\u003eShared Decision-Making\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ihmm6v\" data-start=\"1943\" data-end=\"1967\"\u003eTranslational Research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1969\" data-end=\"2061\"\u003eThe curriculum bridges emerging scientific discoveries with real-world clinical application.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"2063\" data-end=\"2066\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1scsphp\" data-start=\"2068\" data-end=\"2090\"\u003eLearning Objectives\u003c\/h2\u003e\r\n\u003cp data-start=\"2092\" data-end=\"2155\"\u003eUpon completion of this activity, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2157\" data-end=\"2780\"\u003e\r\n \t\u003cli data-section-id=\"1lsu291\" data-start=\"2157\" data-end=\"2238\"\u003eApply updated WHO and ICC lymphoma classification systems in clinical practice.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ko5y7i\" data-start=\"2239\" data-end=\"2319\"\u003eEvaluate current first-line treatment strategies for common lymphoma subtypes.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1r7jh9v\" data-start=\"2320\" data-end=\"2416\"\u003eDiscuss the mechanisms of action, efficacy, and toxicity profiles of novel lymphoma therapies.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ltyvdo\" data-start=\"2417\" data-end=\"2492\"\u003eImplement evidence-based approaches for relapsed and refractory lymphoma.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gzb49t\" data-start=\"2493\" data-end=\"2562\"\u003eIncorporate precision medicine strategies into lymphoma management.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"pjkz2x\" data-start=\"2563\" data-end=\"2638\"\u003eUtilize shared decision-making principles to optimize treatment planning.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"3ujwab\" data-start=\"2639\" data-end=\"2720\"\u003eRecognize emerging developments in lymphoma biology and translational research.\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"uhx3ji\" data-start=\"2721\" data-end=\"2780\"\u003eImprove multidisciplinary collaboration in lymphoma care.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"2782\" data-end=\"2785\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1ti0lfk\" data-start=\"2787\" data-end=\"2809\"\u003eCore Topics Covered\u003c\/h2\u003e\r\n\u003ch3 data-section-id=\"11bad01\" data-start=\"2811\" data-end=\"2846\"\u003eLymphoma Classification Updates\u003c\/h3\u003e\r\n\u003cp data-start=\"2848\" data-end=\"2889\"\u003eThe course reviews major developments in:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2891\" data-end=\"3034\"\u003e\r\n \t\u003cli data-section-id=\"96yo6k\" data-start=\"2891\" data-end=\"2919\"\u003eWHO Classification Updates\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"220pr7\" data-start=\"2920\" data-end=\"2966\"\u003eInternational Consensus Classification (ICC)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1d6ey8u\" data-start=\"2967\" data-end=\"2990\"\u003eMolecular Diagnostics\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"11p3vu8\" data-start=\"2991\" data-end=\"3014\"\u003eBiomarker Integration\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"pgio4d\" data-start=\"3015\" data-end=\"3034\"\u003eDisease Subtyping\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3036\" data-end=\"3133\"\u003eParticipants learn how modern classification systems influence diagnosis and treatment selection.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"3135\" data-end=\"3138\"\u003e\r\n\r\n\u003ch3 data-section-id=\"dk8xbz\" data-start=\"3140\" data-end=\"3160\"\u003eB-Cell Lymphomas\u003c\/h3\u003e\r\n\u003cp data-start=\"3162\" data-end=\"3193\"\u003eComprehensive sessions explore:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3195\" data-end=\"3334\"\u003e\r\n \t\u003cli data-section-id=\"1uz7ted\" data-start=\"3195\" data-end=\"3234\"\u003eDiffuse Large B-Cell Lymphoma (DLBCL)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"6qj6v6\" data-start=\"3235\" data-end=\"3256\"\u003eFollicular Lymphoma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"12z8vgy\" data-start=\"3257\" data-end=\"3279\"\u003eMantle Cell Lymphoma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"cbar52\" data-start=\"3280\" data-end=\"3304\"\u003eMarginal Zone Lymphoma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"19m5t4p\" data-start=\"3305\" data-end=\"3334\"\u003eAggressive B-cell Neoplasms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3336\" data-end=\"3409\"\u003eExperts discuss evolving treatment paradigms and risk-adapted strategies.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"3411\" data-end=\"3414\"\u003e\r\n\r\n\u003ch3 data-section-id=\"135l2el\" data-start=\"3416\" data-end=\"3436\"\u003eHodgkin Lymphoma\u003c\/h3\u003e\r\n\u003cp data-start=\"3438\" data-end=\"3453\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3455\" data-end=\"3574\"\u003e\r\n \t\u003cli data-section-id=\"ncyfc4\" data-start=\"3455\" data-end=\"3474\"\u003eFrontline therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"xjdaqb\" data-start=\"3475\" data-end=\"3496\"\u003eRisk stratification\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"nqij6x\" data-start=\"3497\" data-end=\"3520\"\u003ePET-guided management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"2t19ta\" data-start=\"3521\" data-end=\"3544\"\u003eNovel immunotherapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1kvf8gf\" data-start=\"3545\" data-end=\"3574\"\u003eRelapsed disease management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3576\" data-end=\"3639\"\u003eFaculty review current standards and future directions in care.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"3641\" data-end=\"3644\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1if0mdn\" data-start=\"3646\" data-end=\"3673\"\u003eT-Cell \u0026amp; Rare Lymphomas\u003c\/h3\u003e\r\n\u003cp data-start=\"3675\" data-end=\"3707\"\u003eSpecialized discussions address:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3709\" data-end=\"3838\"\u003e\r\n \t\u003cli data-section-id=\"17mqf9n\" data-start=\"3709\" data-end=\"3738\"\u003ePeripheral T-cell lymphomas\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"169kxzt\" data-start=\"3739\" data-end=\"3760\"\u003eCutaneous lymphomas\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1y9h8jk\" data-start=\"3761\" data-end=\"3785\"\u003eRare lymphoma subtypes\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"17mwdlr\" data-start=\"3786\" data-end=\"3809\"\u003eDiagnostic challenges\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"l1r7ic\" data-start=\"3810\" data-end=\"3838\"\u003eEmerging treatment options\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3840\" data-end=\"3918\"\u003eParticipants gain practical insights into managing uncommon and complex cases.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"3920\" data-end=\"3923\"\u003e\r\n\r\n\u003ch3 data-section-id=\"y7akf3\" data-start=\"3925\" data-end=\"3947\"\u003eNovel Therapeutics\u003c\/h3\u003e\r\n\u003cp data-start=\"3949\" data-end=\"3974\"\u003eThe symposium highlights:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3976\" data-end=\"4104\"\u003e\r\n \t\u003cli data-section-id=\"ovh8sn\" data-start=\"3976\" data-end=\"3999\"\u003eBispecific antibodies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"7pnkqi\" data-start=\"4000\" data-end=\"4026\"\u003eAntibody-drug conjugates\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1xgxd9w\" data-start=\"4027\" data-end=\"4054\"\u003eSmall molecule inhibitors\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1tfouf1\" data-start=\"4055\" data-end=\"4075\"\u003eTargeted therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"191qhy4\" data-start=\"4076\" data-end=\"4104\"\u003eImmunotherapy combinations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4106\" data-end=\"4170\"\u003eExperts review efficacy data and toxicity management strategies.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"4172\" data-end=\"4175\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1o7pqve\" data-start=\"4177\" data-end=\"4199\"\u003eCAR T-Cell Therapy\u003c\/h3\u003e\r\n\u003cp data-start=\"4201\" data-end=\"4219\"\u003eSessions focus on:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4221\" data-end=\"4373\"\u003e\r\n \t\u003cli data-section-id=\"1v51imz\" data-start=\"4221\" data-end=\"4240\"\u003ePatient selection\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"fl0vpw\" data-start=\"4241\" data-end=\"4269\"\u003eCellular therapy logistics\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1e87pq5\" data-start=\"4270\" data-end=\"4291\"\u003eResponse assessment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ay6i8v\" data-start=\"4292\" data-end=\"4325\"\u003eCytokine release syndrome (CRS)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"o443qt\" data-start=\"4326\" data-end=\"4352\"\u003eNeurotoxicity management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"qlh7yw\" data-start=\"4353\" data-end=\"4373\"\u003eLong-term outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4375\" data-end=\"4460\"\u003eParticipants gain updates on one of the most rapidly evolving areas in lymphoma care.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"4462\" data-end=\"4465\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1eo0lvu\" data-start=\"4467\" data-end=\"4501\"\u003eRelapsed \u0026amp; Refractory Lymphoma\u003c\/h3\u003e\r\n\u003cp data-start=\"4503\" data-end=\"4527\"\u003eKey discussions include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4529\" data-end=\"4667\"\u003e\r\n \t\u003cli data-section-id=\"1ch99li\" data-start=\"4529\" data-end=\"4551\"\u003eTreatment sequencing\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"qltdb4\" data-start=\"4552\" data-end=\"4569\"\u003eSalvage therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"17r7hx5\" data-start=\"4570\" data-end=\"4600\"\u003eCellular therapy integration\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"jyaghm\" data-start=\"4601\" data-end=\"4631\"\u003eClinical trial opportunities\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"32s597\" data-start=\"4632\" data-end=\"4667\"\u003ePersonalized treatment strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4669\" data-end=\"4733\"\u003eFaculty review approaches for difficult-to-treat lymphoma cases.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"4735\" data-end=\"4738\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1t4ko6l\" data-start=\"4740\" data-end=\"4787\"\u003ePrecision Medicine \u0026amp; Translational Research\u003c\/h3\u003e\r\n\u003cp data-start=\"4789\" data-end=\"4804\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4806\" data-end=\"4920\"\u003e\r\n \t\u003cli data-section-id=\"xdiuiq\" data-start=\"4806\" data-end=\"4825\"\u003eGenomic profiling\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"18m8fzz\" data-start=\"4826\" data-end=\"4848\"\u003eMolecular biomarkers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1hdcjnd\" data-start=\"4849\" data-end=\"4869\"\u003ePredictive testing\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"awai9f\" data-start=\"4870\" data-end=\"4888\"\u003eTarget discovery\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"x2358v\" data-start=\"4889\" data-end=\"4920\"\u003eFuture therapeutic directions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4922\" data-end=\"4999\"\u003eThe program highlights how advances in biology are transforming patient care.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5001\" data-end=\"5004\"\u003e\r\n\r\n\u003ch3 data-section-id=\"515ol1\" data-start=\"5006\" data-end=\"5032\"\u003eShared Decision-Making\u003c\/h3\u003e\r\n\u003cp data-start=\"5034\" data-end=\"5068\"\u003eParticipants learn strategies for:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5070\" data-end=\"5211\"\u003e\r\n \t\u003cli data-section-id=\"153qnto\" data-start=\"5070\" data-end=\"5102\"\u003ePatient-centered communication\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1xfcyi\" data-start=\"5103\" data-end=\"5131\"\u003eTreatment goal discussions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"15bv4yv\" data-start=\"5132\" data-end=\"5157\"\u003eRisk-benefit assessment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"14u3jw7\" data-start=\"5158\" data-end=\"5181\"\u003eSurvivorship planning\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"77hl7f\" data-start=\"5182\" data-end=\"5211\"\u003eLong-term care coordination\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5213\" data-end=\"5282\"\u003ePractical guidance is provided for individualized treatment planning.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5284\" data-end=\"5287\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1cq7b5x\" data-start=\"5289\" data-end=\"5312\"\u003eEducational Features\u003c\/h2\u003e\r\n\u003cp data-start=\"5314\" data-end=\"5346\"\u003e✔ International Lymphoma Experts\u003c\/p\u003e\r\n\u003cp data-start=\"5348\" data-end=\"5382\"\u003e✔ WHO \u0026amp; ICC Classification Updates\u003c\/p\u003e\r\n\u003cp data-start=\"5384\" data-end=\"5417\"\u003e✔ Precision Oncology Applications\u003c\/p\u003e\r\n\u003cp data-start=\"5419\" data-end=\"5448\"\u003e✔ CAR T-Cell Therapy Advances\u003c\/p\u003e\r\n\u003cp data-start=\"5450\" data-end=\"5479\"\u003e✔ Bispecific Antibody Updates\u003c\/p\u003e\r\n\u003cp data-start=\"5481\" data-end=\"5511\"\u003e✔ Case-Based Panel Discussions\u003c\/p\u003e\r\n\u003cp data-start=\"5513\" data-end=\"5548\"\u003e✔ Translational Research Highlights\u003c\/p\u003e\r\n\u003cp data-start=\"5550\" data-end=\"5591\"\u003e✔ Multidisciplinary Clinical Perspectives\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5593\" data-end=\"5596\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1m9xcqo\" data-start=\"5598\" data-end=\"5616\"\u003eTarget Audience\u003c\/h2\u003e\r\n\u003cp data-start=\"5618\" data-end=\"5643\"\u003eThis course is ideal for:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5645\" data-end=\"5912\"\u003e\r\n \t\u003cli data-section-id=\"rxqb2j\" data-start=\"5645\" data-end=\"5660\"\u003eHematologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1na03fb\" data-start=\"5661\" data-end=\"5682\"\u003eMedical Oncologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"tfvlwf\" data-start=\"5683\" data-end=\"5706\"\u003eRadiation Oncologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1te25c9\" data-start=\"5707\" data-end=\"5727\"\u003eHematopathologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vdecm\" data-start=\"5728\" data-end=\"5758\"\u003eInternal Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"8midow\" data-start=\"5759\" data-end=\"5777\"\u003eOncology Fellows\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"jsq6av\" data-start=\"5778\" data-end=\"5798\"\u003eHematology Fellows\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"biiv77\" data-start=\"5799\" data-end=\"5813\"\u003ePathologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1fmw1r\" data-start=\"5814\" data-end=\"5843\"\u003eAdvanced Practice Providers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1r0141t\" data-start=\"5844\" data-end=\"5866\"\u003eOncology Pharmacists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"kw57hk\" data-start=\"5867\" data-end=\"5893\"\u003eResearchers \u0026amp; Scientists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"alkkvk\" data-start=\"5894\" data-end=\"5912\"\u003eMedical Trainees\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"5914\" data-end=\"5917\"\u003e\r\n\r\n\u003ch2 data-section-id=\"8w266h\" data-start=\"5919\" data-end=\"5948\"\u003eWhy This Course Stands Out\u003c\/h2\u003e\r\n\u003cp data-start=\"5950\" data-end=\"6019\"\u003e✔ Celebrates the 10th anniversary of MSK’s premier lymphoma symposium\u003c\/p\u003e\r\n\u003cp data-start=\"6021\" data-end=\"6075\"\u003e✔ Features internationally recognized lymphoma experts\u003c\/p\u003e\r\n\u003cp data-start=\"6077\" data-end=\"6141\"\u003e✔ Comprehensive review of modern lymphoma classification systems\u003c\/p\u003e\r\n\u003cp data-start=\"6143\" data-end=\"6202\"\u003e✔ Strong focus on emerging therapies and precision medicine\u003c\/p\u003e\r\n\u003cp data-start=\"6204\" data-end=\"6251\"\u003e✔ Covers both common and rare lymphoma subtypes\u003c\/p\u003e\r\n\u003cp data-start=\"6253\" data-end=\"6318\"\u003e✔ Includes practical guidance for relapsed and refractory disease\u003c\/p\u003e\r\n\u003cp data-start=\"6320\" data-end=\"6388\"\u003e✔ Integrates pathology, translational science, and clinical oncology\u003c\/p\u003e\r\n\u003cp data-start=\"6390\" data-end=\"6441\"\u003e✔ Provides immediately applicable clinical insights\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"6443\" data-end=\"6446\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1ilfxpc\" data-start=\"6448\" data-end=\"6479\"\u003eClinical \u0026amp; Educational Value\u003c\/h2\u003e\r\n\u003cp data-start=\"6481\" data-end=\"7030\"\u003eThe \u003cstrong data-start=\"6485\" data-end=\"6570\"\u003eMemorial Sloan Kettering Cancer Center 10th Annual MSK Symposium on Lymphoma 2026\u003c\/strong\u003e provides an in-depth review of the latest advances in lymphoma diagnosis, classification, and treatment. Through expert-led lectures, multidisciplinary discussions, and cutting-edge research updates, participants gain valuable knowledge on modern lymphoma management, novel therapeutics, cellular immunotherapy, and precision oncology. The course equips clinicians with the tools needed to deliver personalized, evidence-based care for patients with lymphoma.\u003c\/p\u003e\r\n\r\n\u003ch2 data-path-to-node=\"6\"\u003eTopics\u003c\/h2\u003e\r\n\u003col start=\"1\" data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003eA “Path” Toward Diagnosis- An Overview of Pathology in Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003eAdvances in Therapeutic Strategies for Mantle Cell Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003eBridging, Debulking, and Beyond- The Multifaceted Role of Radiotherapy with CAR T Cells and Bispecifics\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003eCAR T-Cell Therapy- Lessons Learned from the DESCAR-T Registry\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,4,0\"\u003eConcepts and Controversies in Aggressive B-Cell Lymphoma Classification\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,5,0\"\u003eCurrent Challenges in the Management of Patients with Follicular Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,6,0\"\u003eDebate- Is a Follicular Lymphoma Cure in Reach- T-Cell Engagers versus CAR T-Cell Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,7,0\"\u003eDiffuse Large B-Cell Lymphoma- Diagnosis and Updates on Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,8,0\"\u003eDiffuse Large B-Cell Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,9,0\"\u003eFollicular Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,10,0\"\u003eHodgkin Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,11,0\"\u003eHTLV-1 Clinic Overview\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,12,0\"\u003eHTLV-1-Associated Lymphoma-Leukemia- Biology\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,13,0\"\u003eHTLV-1-Associated Lymphoma-Leukemia- Epidemiology and Natural History\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,14,0\"\u003eHTLV-1-Associated Lymphoma-Leukemia- Therapies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,15,0\"\u003eInnovations in T-Cell Lymphoma- A Winding Road\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,16,0\"\u003eInsights into the Molecular Classification of Diffuse Large B-Cell Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,17,0\"\u003eIntegrative Medicine- Management of Treatment Related Side Effects\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,18,0\"\u003eIntroduction to Cutaneous T-Cell Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,19,0\"\u003eLessons Learned from the Development of T-Cell-Engaging Antibodies in B-Cell Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,20,0\"\u003eMantle Cell Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,21,0\"\u003eMechanisms of Resistance to BTK Degraders\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,22,0\"\u003eOptimizing First-Line Therapy- Balancing Efficacy versus Toxicity\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,23,0\"\u003eOptimizing First-Line Therapy in Diffuse Large B-Cell Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,24,0\"\u003ePanel Discussion and Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,25,0\"\u003ePlenary Lecture- Designing the Next Generation of CAR T-Cell Therapies for Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,26,0\"\u003ePlenary Lecture Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,27,0\"\u003eRecent Advances in the Management of Chronic Lymphocytic Leukemia\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,28,0\"\u003eResearch Spotlight- Bispecific B Cell Protocols at MSK and CRS management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,29,0\"\u003eSkin Considerations for Cutaneous T-Cell Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,30,0\"\u003eSmall Doses, Big Impact- The Role of Very Low-Dose Radiotherapy in Potentially Curable Indolent Lymphomas\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,31,0\"\u003eSpecial Lecture- B-Cell Development and Lineage Stability\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,32,0\"\u003eSpecial Lecture- How to Interpret “Real-World” Data\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,33,0\"\u003eSpotlight on New Agents and MSK Clinical Trials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,34,0\"\u003eSpotlight on Nodular Lymphocyte Predominant B-Cell- Hodgkin Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,35,0\"\u003eSpotlight on Recent Drugs and MSK Clinical Trials – 01\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,36,0\"\u003eSpotlight on Recent Drugs and MSK Clinical Trials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,37,0\"\u003eT-Cell Lymphoma Panel Discussion and Q\u0026amp;A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cdiv data-headlessui-state=\"open\"\u003e\r\n\u003cdiv class=\"opx-4 md:px-7 py-3 rounded-lg\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Meducourse","offers":[{"title":"Default Title","offer_id":43066691256418,"sku":"MED-AMB09433","price":55.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Memorial-Sloan-Kettering-Cancer-Center-10th-Annual-MSK-Symposium-on-Lymphoma-2026.jpg?v=1782499365","url":"https:\/\/meducourse.com\/products\/memorial-sloan-kettering-cancer-center-10th-annual-msk-symposium-on-lymphoma-2026","provider":"Meducourse","version":"1.0","type":"link"}